To tackle the human health challenges that face the world today, the FNIH develops collaborations with top experts from government, industry, academia and the not-for-profit sector and provides a neutral environment where we can work productively toward a common goal.

Etiology, Risk Factors and Interactions of Enteric Infections and Malnutrition and the Consequences for Child Health and Development (MAL-ED)

The study was implemented using shared and harmonized protocols across the eight sites to gather an enormous amount of data (physical, cognitive assessments, diet, illness and enteric infection, socio-economic status, etc.) to enable identification and characterization of factors associated with negative impacts on a child’s growth, development and vaccine response early in life.

Global Health Fund

The Global Health Fund supports FNIH programs that are designed to alleviate widespread suffering in the developing world. Program focus includes research and training on diseases such as malaria and HIV, as well as conditions like malnutrition that afflict hundreds of millions of people globally.

Rapid identification of individuals with viable adult female worms of Onchocerca volvulus: a means to the end

To identify host- and parasite-specific biomarker(s) present in human subjects with viable adult females of Onchocerca volvulus (Ov) and to develop and configure rapid point of care methods to detect (or sense) these biomarkers.

Identification of high-quality HITs for tuberculosis (HIT-TB)

To produce high-quality chemical hit series with defined, tractable targets as drug leads for tuberculosis.

Centralized Envelope Comparative Immunogenicity Study

The Centralized Envelope Comparative Immunogenicity Study is an HIV/AIDS vaccine development project that seeks to answer a central question that has blocked the development of a successful HIV vaccine: how can we design vaccine immunogens that address the broad genetic diversity of HIV?

Support of Ebola Research by NIAID

In response to the critical Ebola Virus Disease (EVD) outbreak in 2014, the FNIH has established a fund that supports the Division of Clinical Research of the National Institute of Allergy and Infectious Diseases (NIAID) in its efforts to prevent, treat and research the EVD in West Africa.

Biomarkers Consortium - Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia Clinical Endpoint Development (HABP/VABP)

The Biomarkers Consortium’s Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) Project aims to develop clinically relevant endpoints in clinical trials to improve antibacterial trial feasibility.

Biomarkers Consortium - Developing Endpoints for Clinical Trials in Community Acquired Bacterial Pneumonia (CABP) and Acute Skin and Skin Infections (ABSSSI)

The Biomarkers Consortium’s Developing Endpoints for Clinical Trials in CABP and Skin Infections aims to develop approaches that will help the U.S. Food and Drug Administration develop efficacy outcome measures (endpoints) for modern-day clinical trials of investigational agents for community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).